Results 51 to 60 of about 22,530 (241)

Oligonucleotides as Radiopharmaceuticals

, 2006
Oligonucleotide radiopharmaceuticals is a slowly but steadily progressing field. With a panel of labeling and imaging techniques mastered by several groups, imaging of oligonucleotides is now relatively accessible and will be applied to more and more trials of oligonucleotide pharmacology.
openaire   +3 more sources

Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile

Molecules, 2020
The concept of using ibuprofen as an albumin-binding entity was recently demonstrated by the development of [177Lu]Lu-Ibu-PSMA-01. In the present study, we designed a novel ibuprofen-containing radioligand (Ibu-PSMA-02) with subtle structural changes ...
Luisa M. Deberle, Viviane J. Tschan, Francesca Borgna, Fan Sozzi-Guo, Peter Bernhardt, Roger Schibli, Cristina Müller   +6 more
doaj   +1 more source

Hollow-fiber bioreactor production of extracellular vesicles from human bone marrow mesenchymal stromal cells yields nanovesicles that mirrors the immuno-modulatory antigenic signature of the producer cell

Stem Cell Research & Therapy, 2021
Background Extracellular vesicles (EVs) produced by human bone marrow-derived mesenchymal stromal cells (hBM-MSCs) are currently investigated for their clinical effectiveness towards immune-mediated diseases.
Jonathan Gobin, Gauri Muradia, Jelica Mehic, Carole Westwood, Lauren Couvrette, Andrew Stalker, Stewart Bigelow, Christian C. Luebbert, Frédéric St-Denis Bissonnette, Michael J. W. Johnston, Simon Sauvé, Roger Y. Tam, Lisheng Wang, Michael Rosu-Myles, Jessie R. Lavoie   +14 more
doaj   +1 more source

An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment

BMC Cancer, 2017
Background Novel theranostic options for high-risk non-muscle invasive bladder cancer are urgently needed. This requires a thorough evaluation of experimental approaches in animal models best possibly reflecting human disease before entering clinical ...
Doreen Huebner, Christiane Rieger, Ralf Bergmann, Martin Ullrich, Sebastian Meister, Marieta Toma, Ralf Wiedemuth, Achim Temme, Vladimir Novotny, Manfred P. Wirth, Michael Bachmann, Jens Pietzsch, Susanne Fuessel   +12 more
doaj   +1 more source

Evaluation of Actinium-225 Labeled Minigastrin Analogue [²²⁵Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy

Pharmaceutics, 2020
The overexpression of cholecystokinin B receptor (CCKBR) in human cancers led to the development of radiolabeled minigastrin analogues for targeted radionuclide therapy, which aims to deliver cytotoxic radiation specifically to cancer cells.
Yun Qin, Stefan Imobersteg, Alain Blanc, Stephan Frank, Roger Schibli, Martin P. Béhé, Michal Grzmil   +6 more
doaj   +1 more source

Brain MRI-to-PET Synthesis using 3D Convolutional Attention Networks [PDF]

arXiv, 2022
Accurate quantification of cerebral blood flow (CBF) is essential for the diagnosis and assessment of a wide range of neurological diseases. Positron emission tomography (PET) with radiolabeled water (15O-water) is considered the gold-standard for the measurement of CBF in humans. PET imaging, however, is not widely available because of its prohibitive
arxiv  

Unconventional Nuclides for Radiopharmaceuticals

Molecular Imaging, 2010
Rapid and widespread growth in the use of nuclear medicine for both diagnosis and therapy of disease has been the driving force behind burgeoning research interests in the design of novel radiopharmaceuticals. Until recently, the majority of clinical and basic science research has focused on the development of 11C-, 13N-, 15O-, and 18F ...
Jason S. Lewis, Jason P. Holland, Matthew J. Williamson   +2 more
openaire   +4 more sources

Production of the PET radionuclide 61Cu via the 62Ni(p,2n)61Cu nuclear reaction

EJNMMI Radiopharmacy and Chemistry
Background There are only a handful of true theranostic matched pairs, and in particular the theranostic radiocopper trio 61Cu, 64Cu and 67Cu, for diagnosis and therapy respectively, is a very attractive candidate. In fact, the alternative of two imaging
Santiago Andrés Brühlmann, Martin Walther, Klaus Kopka, Martin Kreller   +3 more
doaj   +1 more source

Radiopharmaceuticals in Acute Porphyria

Clinical Therapeutics, 2016
The acute porphyrias are a group of rare metabolic disorders of the heme biosynthetic pathway. Carriers of the acute porphyria gene are prone to potentially fatal acute attacks, which can be precipitated by drug exposure. It is therefore important to know whether a drug is safe for carriers of the acute porphyria gene.
Nanno Schreuder, Ilahä Mamedova, Frank G A Jansman   +2 more
openaire   +3 more sources

Scalability study on [133La]LaCl3 production with a focus on potential clinical applications

EJNMMI Radiopharmacy and Chemistry
Background In recent years, targeted alpha therapy has gained importance in the clinics, and in particular, the alpha-emitter 225Ac plays a fundamental role in this clinical development.
Santiago Andrés Brühlmann, Martin Walther, Magdalena Kerstin Blei, Constantin Mamat, Klaus Kopka, Robert Freudenberg, Martin Kreller   +6 more
doaj   +1 more source